Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Ovarian Cancer
- Type
- Observational
- Design
- Observational Model: OtherTime Perspective: Other
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Only males
Description
A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.
A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.
Tracking Information
- NCT #
- NCT04724031
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon